8EV Stock Overview
A clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Theracryf Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0005 |
| 52 Week High | UK£0.01 |
| 52 Week Low | UK£0.0005 |
| Beta | 1.42 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -90.00% |
| 33 Year Change | -99.12% |
| 5 Year Change | -99.38% |
| Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8EV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.02% | -1.5% |
| 1Y | -90.0% | -17.7% | 7.9% |
Return vs Industry: 8EV underperformed the German Biotechs industry which returned -17.7% over the past year.
Return vs Market: 8EV underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 8EV volatility | |
|---|---|
| 8EV Average Weekly Movement | 0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 8EV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 9 | Huw Jones | theracryf.com |
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company’s lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy.
Theracryf Plc Fundamentals Summary
| 8EV fundamental statistics | |
|---|---|
| Market cap | €2.70m |
| Earnings (TTM) | -€3.75m |
| Revenue (TTM) | €473.82k |
5.7x
P/S Ratio-0.7x
P/E RatioIs 8EV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8EV income statement (TTM) | |
|---|---|
| Revenue | UK£396.00k |
| Cost of Revenue | UK£3.95m |
| Gross Profit | -UK£3.55m |
| Other Expenses | -UK£414.00k |
| Earnings | -UK£3.14m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -0.0073 |
| Gross Margin | -896.72% |
| Net Profit Margin | -792.17% |
| Debt/Equity Ratio | 0% |
How did 8EV perform over the long term?
See historical performance and comparison